Granted Patent B2

US 12,503,463 · App. 17/612,099 · Granted Dec 23, 2025

Inventors: Yuki Fujii (Tokyo, JP); Masayuki Sakuma (Tokyo, JP); Yoshinori Aihara (Osaka, JP); Jeremy Besnard (Eynsham, GB); Andrew Simon Bell (Deal, GB)

Assignee: SUMITOMO PHARMA CO., LTD.

C07D413/14C07D401/04C07D413/04

Abstract

Claims (33)

1 . A compound of Formula (1):

or a pharmaceutically acceptable salt thereof,

wherein

Z is a nitrogen atom or —CR A —;

Y is carbonyl or sulfonyl;

m is 1, 2, 3, or 4;

n is 0, 1, 2, or 3;

provided that when Y is sulfonyl, n is not 0;

R A is hydrogen, hydroxy, C 1-6 alkyl, or C 1-6 alkoxy;

R 1a , R 1b , R 1c , and R 1d are each independently hydrogen, hydroxy, halogen, or C 1-6 alkyl optionally-substituted with the same or different 1 to 3 halogen;

R 2a , R 2b , R 2c , and R 2d are each independently, and each of R 2c s or each of R 2d s is independently when R 2c or R 2d exists plurally, hydrogen, halogen, or C 1-6 alkyl (wherein the alkyl may be optionally substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen, hydroxy, C 3-8 cycloalkyl, and C 1-6 alkoxy), provided that when R 2a and R 2b , or R 2c and R 2d which attach to the same carbon atom are each independently the said C 1-6 alkyl, they may be combined together with the carbon atom to which they attach to form a 3 to 6-membered saturated carbocycle;

R 3 is C 1-6 alkyl, wherein the alkyl may be optionally substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen, hydroxy, cyano, C 3-8 cycloalkyl, and C 1-6 alkoxy;

R 4a , R 4b , R 4c , and R 4d are each independently, and each of R 4c s or each of R 4d s is independently when R 4c or R 4d exists plurally, hydrogen, halogen, C 1-6 alkyl (wherein the alkyl may be optionally substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen, hydroxy, cyano, C 3-8 cycloalkyl, C 1-6 alkoxy, C 1-6 alkyl ester, and amino optionally-substituted with the same or different 1 or 2 C 1-6 alkyl (wherein the alkyl may be optionally substituted with oxo)), C 2-6 alkynyl, or amino (wherein the amino may be optionally substituted with the same or different 1 or 2 C 1-6 alkyl); provided that when any two of R 4a , R 4b , R 4c , and R 4d are each independently the said C 1-6 alkyl, they may be combined together with the carbon atom or the carbon atoms to which they attach to form a 3- to 6-membered saturated carbocycle or a 4- to 6-membered saturated heterocycle wherein when the said C 1-6 alkyl groups have a substituent, the substituent may be included as a ring member of the carbocycle or heterocycle;

provided that when Y is sulfonyl and n is 1, any one of R 4c or R 4d is hydrogen; and when Y is sulfonyl and n is 2 or 3, any one of R 4c or R 4d which binds to the carbon atom adjacent to Y is hydrogen; and

Ring Q is a group of the following Formula (2a), (2b), (2c), (2d), (2e), or (2f):

wherein

R 5a , R 5b , R 5c , and R 5d are each independently hydrogen, halogen, cyano, C 1-6 alkyl, C 1-6 alkoxy (wherein the alkyl and the alkoxy may be optionally each independently substituted with the same or different 1 to 3 halogen), or amino optionally-substituted with the same or different 1 or 2 C 1-6 alkyl; and

R 6 is hydrogen, C 1-6 alkyl, or C 3-8 cycloalkyl, wherein the alkyl and the cycloalkyl may be optionally each independently substituted with the same or different 1 to 3 halogen.

2 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 1a , R 1b , R 1c , and R 1d are hydrogen.

3 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 2a , R 2b , R 2c , and R 2d are hydrogen.

4 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein m is 1.

5 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 3 is C 1-6 alkyl.

6 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Z is —CR A —.

7 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R A is hydrogen.

8 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5a , R 5b , R 5c , and R 5d are each independently hydrogen, halogen, or C 1-6 alkyl.

9 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5a , R 5c , and R 5d are hydrogen.

10 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 5b is hydrogen, halogen, or C 1-6 alkyl.

11 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 6 is hydrogen.

12 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein R 4a , R 4b , R 4c , and R 4d are each independently, and each of R 4c s or each of R 4d s is independently when R 4c or R 4d exists plurally, hydrogen, halogen, or C 1-6 alkyl, wherein the alkyl may be optionally substituted with the same or different 1 to 5 substituents selected from the group consisting of halogen, hydroxy, and C 1-6 alkoxy.

13 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein n is 0 or 1.

14 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y is carbonyl.

15 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein Y is sulfonyl.

16 . The compound of claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

Assignments (2)

Priority Claims (1)

Continuity (1)

References Cited (28)